These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 11516092)
1. Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience. Razzouk BI; Raimondi SC; Srivastava DK; Pritchard M; Behm FG; Tong X; Sandlund JT; Rubnitz JE; Pui CH; Ribeiro RC Leukemia; 2001 Sep; 15(9):1326-30. PubMed ID: 11516092 [TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821. Chang M; Raimondi SC; Ravindranath Y; Carroll AJ; Camitta B; Gresik MV; Steuber CP; Weinstein H Leukemia; 2000 Jul; 14(7):1201-7. PubMed ID: 10914543 [TBL] [Abstract][Full Text] [Related]
3. Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia. Fouillard L; Labopin M; Meloni G; Polge E; Gorin NC; Frassoni F Haematologica; 2004 Jan; 89(1):107-8. PubMed ID: 14754615 [No Abstract] [Full Text] [Related]
4. Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia. Wahlin A; Brinch L; Hörnsten P; Evensen SA; Oberg G; Simonsson B; Hedenus M Eur J Haematol; 1997 Apr; 58(4):233-40. PubMed ID: 9186533 [TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA; J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813 [TBL] [Abstract][Full Text] [Related]
6. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients. Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475 [TBL] [Abstract][Full Text] [Related]
7. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. Krance RA; Hurwitz CA; Head DR; Raimondi SC; Behm FG; Crews KR; Srivastava DK; Mahmoud H; Roberts WM; Tong X; Blakley RL; Ribeiro RC J Clin Oncol; 2001 Jun; 19(11):2804-11. PubMed ID: 11387351 [TBL] [Abstract][Full Text] [Related]
8. Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: correlations with clinical characteristics and outcome. Manola KN; Panitsas F; Polychronopoulou S; Daraki A; Karakosta M; Stavropoulou C; Avgerinou G; Hatzipantelis E; Pantelias G; Sambani C; Pagoni M Cancer Genet; 2013 Mar; 206(3):63-72. PubMed ID: 23411131 [TBL] [Abstract][Full Text] [Related]
9. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ; Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167 [TBL] [Abstract][Full Text] [Related]
10. Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults. Min GJ; Kim HJ; Yoon JH; Kwak DH; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS Biol Blood Marrow Transplant; 2018 Aug; 24(8):1621-1628. PubMed ID: 29698793 [TBL] [Abstract][Full Text] [Related]
11. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M; Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916 [TBL] [Abstract][Full Text] [Related]
12. Purine nucleoside analogues in the treatment of myleoid leukemias. Robak T Leuk Lymphoma; 2003 Mar; 44(3):391-409. PubMed ID: 12688309 [TBL] [Abstract][Full Text] [Related]
13. Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Seymour JF; Juneja SK; Campbell LJ; Ellims PH; Estey EH; Prince HM Leukemia; 1999 Nov; 13(11):1735-40. PubMed ID: 10557046 [TBL] [Abstract][Full Text] [Related]
14. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group. Klein K; Kaspers G; Harrison CJ; Beverloo HB; Reedijk A; Bongers M; Cloos J; Pession A; Reinhardt D; Zimmerman M; Creutzig U; Dworzak M; Alonzo T; Johnston D; Hirsch B; Zapotocky M; De Moerloose B; Fynn A; Lee V; Taga T; Tawa A; Auvrignon A; Zeller B; Forestier E; Salgado C; Balwierz W; Popa A; Rubnitz J; Raimondi S; Gibson B J Clin Oncol; 2015 Dec; 33(36):4247-58. PubMed ID: 26573082 [TBL] [Abstract][Full Text] [Related]
15. Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate. Arahata M; Shimizu Y; Asakura H; Nakao S J Hematol Oncol; 2015 Feb; 8():5. PubMed ID: 25652695 [TBL] [Abstract][Full Text] [Related]
16. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. Kudo K; Kojima S; Tabuchi K; Yabe H; Tawa A; Imaizumi M; Hanada R; Hamamoto K; Kobayashi R; Morimoto A; Nakayama H; Tsuchida M; Horibe K; Kigasawa H; Tsukimoto I; J Clin Oncol; 2007 Dec; 25(34):5442-7. PubMed ID: 18048827 [TBL] [Abstract][Full Text] [Related]
17. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Huismans DR; Zimmermann M; Harbott J; Slater RM; Creutzig U; Veerman AJ Blood; 2002 Nov; 100(9):3352-60. PubMed ID: 12384437 [TBL] [Abstract][Full Text] [Related]
18. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia. Aldoss I; Ji L; Haider M; Pullarkat V Acta Haematol; 2014; 131(4):202-7. PubMed ID: 24296475 [TBL] [Abstract][Full Text] [Related]
19. Characteristics and clinical evolution of patients with acute myeloblastic leukemia in northeast Mexico: an eight-year experience at a university hospital. Jaime-Pérez JC; Brito-Ramirez AS; Pinzon-Uresti MA; Gutiérrez-Aguirre H; Cantú-Rodríguez OG; Herrera-Garza JL; Gomez-Almaguer D Acta Haematol; 2014; 132(2):144-51. PubMed ID: 24556725 [TBL] [Abstract][Full Text] [Related]
20. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). Wrzesień-Kuś A; Robak T; Lech-Marańda E; Wierzbowska A; Dmoszyńska A; Kowal M; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Maj S; Hellmann A; Skotnicki A; Jedrzejczak W; Kuliczkowski K; Eur J Haematol; 2003 Sep; 71(3):155-62. PubMed ID: 12930315 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]